Financial Consulate, Inc Abb Vie Inc. Transaction History

Financial Consulate, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 17, 2023	BUY	$144.61 - $166.54 $5,061 - $5,828	35 Added 1.41%	2,514 $400,000
Q4 2022 Jan 11, 2023	SELL	$138.31 - $165.87 $138,171 - $165,704	-999 Reduced 28.72%	2,479 $0
Q3 2022 Oct 20, 2022	BUY	$134.21 - $153.93 $268 - $307	2 Added 0.06%	3,478 $467,000
Q2 2022 Jul 19, 2022	BUY	$137.62 - $174.96 $137 - $174	1 Added 0.03%	3,476 $532,000
Q1 2022 Apr 28, 2022	BUY	$131.98 - $163.75 $23,888 - $29,638	181 Added 5.49%	3,475 $563,000
Q4 2021 Feb 07, 2022	BUY	$107.43 - $135.93 $107 - $135	1 Added 0.03%	3,294 $446,000
Q3 2021 Oct 19, 2021	BUY	$106.4 - $120.78 $106,612 - $121,021	1,002 Added 43.74%	3,293 $355,000
Q2 2021 Jul 22, 2021	BUY	$105.21 - $117.21 $2,735 - $3,047	26 Added 1.15%	2,291 $258,000
Q1 2021 Apr 19, 2021	BUY	$102.3 - $112.62 $204 - $225	2 Added 0.09%	2,265 $245,000
Q4 2020 Jan 29, 2021	BUY	$80.49 - $108.67 $182,148 - $245,920	2,263 New	2,263 $243,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Financial Consulate, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Consulate, Inc with notifications on news.